Cytokinetics (CYTK) stock closes up 3.5% into year-end as Myqorzo launch nears, insider sale disclosed
Cytokinetics shares closed up 3.5% at $63.54, ahead of the planned U.S. launch of Myqorzo for obstructive hypertrophic cardiomyopathy. EVP Andrew Callos sold 1,809 shares at $62.44 under a preset trading plan, retaining 51,353 shares. Investors await U.S. pricing, early prescription data, and a late February earnings update. Myqorzo carries a boxed warning and REMS safety requirements.
